Funding Opportunities

Limited Submission Opportunities

(Applications through LSO office)

Intramural Funding Opportunities

  • Deadline: Apr 19, 2021
    Computational Cancer Research RFA

    Thanks to a generous donation, the Helen Diller Family Comprehensive Cancer Center is requesting applications for projects in computational cancer research, highlighting a new initiative in the Cancer Center focusing on Data Science.
  • Deadline: Apr 19, 2021
    Artificial Intelligence, Imaging and Cancer RFA

    Thanks to a generous donation, the Helen Diller Family Comprehensive Cancer Center is requesting applications for projects that apply machine learning or artificial intelligence (AI) techniques to imaging data in cancer. The project should focus on an innovative idea using imaging data along with AI to improve diagnosis, treatment selection, response assessment, or prognosis of cancer.
  • Deadline: Apr 23, 2021
    HDFCCC Remembering Community Health in Basic Research Pilot Awards
    Request for Application 2021

    One of the goals of the Helen Diller Family Comprehensive Cancer Center (HDFCCC) is to support basic science research that addresses cancers specifically impacting our area residents. Such research is facilitated by establishing strong relationships with community members and local groups. To help accomplish this goal, HDFCCC will be funding 2 pilot projects aimed at helping basic science trainees build these types of relationships. The projects must be community-facing and must address a cancer-related challenge relevant to residents of our catchment area (48 counties from San Luis Obispo to the Oregon border).

Foundations/Other Sources

  • Deadline: April 19, 2021
    NCCN Request for Proposals (RFP): Phase I/II Clinical and/or Correlative Studies of the panHER Inhibitor Neratinib in the Treatment of Breast, Gastrointestinal, Lung, and Neurological Cancers

    This research grant will support the conduct of clinical and correlative studies to evaluate the effectiveness of neratinib in the treatment of breast, gastrointestinal (GI), lung and certain neurological cancers. It is anticipated that proposals submitted in response to this RFP will be useful in guiding further clinical development of neratinib. Clinical studies with correlative endpoints are encouraged.
  • Deadline: April 22, 2021
    NCI/CRUK Cancer Grand Challenges

    The National Cancer Institute (NCI) and Cancer Research UK (CRUK), the world’s leading funders of cancer research, are partnering to fund the Cancer Grand Challenges (CGC) program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer.
  • Deadline: April 29, 2021
    Kidney Cancer Association Grants
    • Advanced Discovery Award
    • Young Investigator Award
    • Psychosocial Focus Award
  • Deadline: April 30, 2021
    2021 BridgeBio Rare Diseases Collaboration Program

    BridgeBio is looking for principal investigators studying rare disease therapeutics that may be interested in collaborating. BridgeBio is agnostic to disease area and therapeutic modality as long as drugs are directly compensating for a genetic alteration in diseases (e.g., inhibiting a mutated protein, replacing a defective gene, etc.). These collaborations can help advance an early-stage therapeutic idea to the point of a NewCo and to clinical trials. 
  • LOI Deadline: May 3, 2021
    The Mark Foundation for Cancer Research Emerging Leader Award Program

    Supports innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.
  • LOI Deadline: May 3, 2021
    NCCN/AstraZeneca Initiative Request for Proposals (RFP) in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC)  

    This opportunity is seeking proposals to improve patient care and outcomes in early-stage non-small cell lung cancer (NSCLC). Multiple factors contribute to the complexity of treating the disease, including screening, staging, surgical or other local treatment options, and adjuvant systemic therapy.  
  • LOI Deadline: May 14, 2021
    NCCN/Pfizer/Astellas Request for Proposals (RFP): Enzalutamide in the Treatment of Prostate Cancer

    This grant will promote the advancement of scientific knowledge concerning the mechanisms of actions, underlying biology, and clinical effectiveness of enzalutamide in prostate cancer. The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged.
  • Pre-app Deadline: July 29, 2021
    Department of Defense Peer Reviewed Cancer Research Program Funding Opportunities
    • Behavioral Health Science Award
    • Career Development Award - Fellow Option    
    • Translational Team Science Award    
  • Deadline: rolling basis through Jan 31, 2022
    Partnership for Accelerating Cancer Therapies (PACT) Clinical Trials RFA 

    The Foundation for the NIH has issued an RFA for novel biomarkers to support the Partnership for Accelerating Cancer Therapies (PACT). The overall goal for this RFA is to solicit clinical trials to partner with the PACT initiative to provide biospecimens for exploratory deep immunoprofiling analysis, employing this standardized set of biomarker assays. The data from this immunoprofiling, along with the necessary de-identified clinical data from the trials, will be placed into the CIDC to continue to build a large body of standardized immunoprofiling data that can be used to validate existing biomarkers for clinical trial and regulatory use, and importantly, to develop new validated biomarkers for these purposes. Development and validation of these biomarkers will allow the immuno-oncology field to more accurately pair patients with novel immunotherapies being developed.